{
    "root": "bf748572-feba-4465-99e0-234e04a63cfc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ENCELTO",
    "value": "20250321",
    "ingredients": [
        {
            "name": "REVAKINAGENE TARORETCEL",
            "code": "Q7V7NYG6GM"
        }
    ],
    "indications": "ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).",
    "contraindications": "For intravitreal implantation only. ENCELTO is intended for surgical intravitreal implantation under aseptic conditions by a qualified ophthalmologist. ( 2.1 ) The recommended dose is one ENCELTO implant per affected eye containing 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF). ( 2.1 ) Carefully inspect ENCELTO prior to use and refer to the Instructions for Use when preparing for and performing surgical placement or removal of ENCELTO. ( 2.2 , 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "ENCELTO is contraindicated in patients with: \n                  \n                  \n                     Active or suspected ocular or periocular infections. Â \n                     Known hypersensitivity to Endothelial Serum Free Media (Endo-SFM)"
}